-1.23% for AstraZeneca stock amid US FDA scrutiny of camizestrant and Truqap

Traders Union
All News
Financial News
AstraZeneca slides 1.23% to GBX13698.00

Highlights

AstraZeneca received US FDA approval for Breztri Aerosphere, the first triple inhaler for asthma maintenance in patients 12 and older.
FDA raised concerns over trial design and data reliability for AstraZeneca’s oncology candidates, potentially impacting future drug approvals.
AstraZeneca shares remain under selling pressure with bearish technical momentum, expected to range between GBX 13,400 and GBX 14,100 over the next week.

FDA approvals and trial concerns drive mixed sentiment despite ongoing selloff

The US FDA granted approval to AstraZeneca's Breztri Aerosphere as the first single-inhaler triple therapy for asthma maintenance treatment in individuals aged 12 and older. AstraZeneca and Amgen have begun real-time clinical trials with the FDA through a pilot program to support expedited drug development using AI and data science, which includes AstraZeneca’s phase 2 Traverse trial for a BTK inhibitor in mantle cell lymphoma. The FDA also released briefing documents expressing concerns about the company’s cancer drugs camizestrant and Truqap, citing questions on trial design and data meaningfulness ahead of an advisory committee meeting. These developments occurred though price action has remained under broader selling pressure.

Oversold readings deepen as price holds above long-term support

AZN is currently positioned at GBX 13,698.00, notably below the MA-20 at GBX 14,774.40 and MA-50 at GBX 14,728.12, while maintaining support above the MA-200 at GBX 13,191.21. The immediate resistance lies at the Ichimoku Kijun level of GBX 13,902.00. Daily momentum readings show negative MACD and AO values, a neutral but weak ADX on the D1, and a downtrend on the W1. RSI, Stoch RSI, CCI, and BBP all register oversold conditions, with intraday trading exhibiting a small downward gap, pressed near the day’s low and reflecting persistent selling activity.

High downside risk expected as price remains locked in narrow range

Over the next five trading days, AZN is likely to fluctuate within a volatility band between GBX 13,400 and GBX 14,100. The probability of a continued decline remains high, and chances of a short-term rebound are estimated below 20%. The baseline scenario anticipates range-bound movement as oversold readings are absorbed. A bullish move above GBX 13,902.00 could target the upper boundary, while losing support at the MA-200 near GBX 13,191.21 could accelerate declines into the lower GBX 13,000s.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca weathering short-term volatility amid heavy selling pressure. He believes recent regulatory milestones and collaborations reflect strong underlying fundamentals. The long-term outlook remains constructive as price holds above the MA-200 and clinical advancements support sentiment. Karapetjanc emphasizes near-term risks, but maintains confidence in the company's recovery potential. "I expect renewed momentum for AZN if the price stays above key support and news-driven optimism persists."

Earlier, analysts noted that AstraZeneca’s constructive outlook remained supported by ongoing drug development progress despite intermittent selling pressures. The recent developments—including new regulatory milestones and technical breakdowns—now add a more cautious tone, making the ability to hold above the MA-200 level a critical gauge for downside risk in the coming sessions.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.